Indications
Vitekta co-administered with a ritonavir-boosted protease inhibitor and with other antiretroviral agents, is indicated for the treatment of human-immunodeficiency-virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir.
Composition
- Active substance
- elvitegravir
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vitekta
- Active substance
- elvitegravir
- ATC code
- J05AX11
- Therapeutic area
- HIV Infections
- Marketing authorisation holder
- Gilead Sciences International Ltd